# A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors

> **NCT05781360** · PHASE1 · TERMINATED · sponsor: **Jiangsu Simcere Pharmaceutical Co., Ltd.** · enrollment: 192 (actual)

## Conditions studied

- Locally Advanced Unresectable or Metastatic Solid Tumor

## Interventions

- **DRUG:** SIM0237

## Key facts

- **NCT ID:** NCT05781360
- **Lead sponsor:** Jiangsu Simcere Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-08
- **Primary completion:** 2024-05-25
- **Final completion:** 2024-05-25
- **Target enrollment:** 192 (ACTUAL)
- **Why stopped:** An internal business decision, not based on safety or regulatory considerations.
- **Last updated:** 2024-12-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05781360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05781360, "A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05781360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*